Background: Immune checkpoint inhibitors (ICI) induce durable tumor responses and increased overall survival (OS) of cancer patients. Patients with low PD-L1, low tumor mutational burden (TMB) or without intra-tumoral CD8þ T cells, have a poor response rate to ICIs. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10, which overcomes tumor immune escape by stimulating the activation, survival and clonal expansion of intra-tumoral, tumor antigen specific CD8þ T cells. Pegilodecakin up-regulates IFNc in CD8þ T cells and MHC expression, which facilitates antigen presentation even in tumors with low CD8þ T cells and low TMB. Here we explore the combination of Pegilodecakin with SOC docetaxel in an ICI resistant mouse triple negative breast cancer model. Methods: 4T1 cells were established SC for two weeks prior to treatment. Pegilodecakin was administered at suboptimal doses, docetaxel was dosed at the MTD. Quantitation of T cell infiltration and tumor cell death was quantified by IHC. Intra-tumoral and systemic cytokine and T cell activity were evaluated. Results: Docetaxel did not induce regressions but inhibited tumor growth by 65%. Pegilodecakin alone induced tumor growth inhibition and delayed tumor regression in 75% of mice with an 80% reduction of tumor size after 4 weeks of treatment. Pegilodecakin þ docetaxel lead to a synergistic tumor control and complete responses in 75% of mice. While pegilodecakin induced T cell infiltration and tumor cell apoptosis with 95% of the measurable tumor being reduced to scar tissue, the tumor size initially continued to increase, indicative of pseudo-progression. In contrast, Pegilodecakin / docetaxel therapy led to a complete eradication of the tumor without pseudoprogression.
Background: Tumors with a phenotype associated with a high mutational load such as POLE-mutated or those showing microsatellite instability (MSI) are more likely to have clinical responses to immune-checkpoints blockade therapy. Indeed, several clinical trials are currently on-going targeting PD-1 in a variety of cancer types. However, some of these patients do not respond to immunotherapy. Recently, mutations in JAK1 and JAK2 has been reported to be responsible for this resistance. Methods: Here we explore the effect of functional mutations in genes in the interferon gamma (IFG) signaling and antigen presentation (AP) pathway in endometrial, colorectal, and gastric POLE-mutated and MSI tumors extracted from TCGA. Results: As a result, we have found that POLE-MSI tumors accumulated more mutations in IFG and AP pathways than randomly expected. Using gene expression data, we corroborate that IFN pathway is under-expressed in IGF/AP mutant tumors. MSI IGF/ AP mutant tumors over-express T cell receptor pathway probably as a compensatory mechanism. Moreover, when cell infiltration was assessed, these tumors have a tendency to present higher levels of cytotoxic lymphocytes than non-mutated tumors. However, they showed over-expression of pathways related to anti-PD1 resistance such as epithelial to mesenchymal transition or angiogenesis. These results suggest that despite being infiltrated, IGF/AP mutant tumors are able to evade immune surveillance. Regarding survival, although overall these tumors have a very good prognosis, we observed that IGF/AP mutated endometrial tumors showed higher clinical grade than the non-mutated ones. Conclusions: Based on these results, we show that regardless of cancer type, HiMut tumors with functional mutations in IFG and AP pathways shows a more aggressive phenotype, and present activation of cellular processes that have been related to immune-resistance, probably to evade destruction by a very active T-cell stroma due to the high amount of neoantigens. This phenotype is even more evident in ultra-mutated POLE tumors. Therefore, HiMut tumors could be exploited as a surrogate to understand mechanisms of immune-resistance. Background: While anti-CTLA4 immunotherapy (IT) improves survival in metastatic melanoma patients, it manifests with severe toxicity. Recently, we identified serum antibody signatures associated with toxicity outcomes following anti-CTLA4 IT. In this study, capitalizing on our recent data showing that the expression of autoimmunity risk genes is controlled by germline genetic variation in melanoma survival, we tested whether antibody profiles linked with IT-related toxicity are impacted by underlying genetic variation. Methods: We have integrated serum data from 37 anti-CTLA4 IT-treated patients, profiled by HuProt human proteome array with germline whole-exome sequencing (WXS), comparing 28 patients with none/mild toxicity (CTCAE score 0-2) and 9 patients with severe toxicity (CTCAE score 3-5). The associations between toxicity and germline genetic variation were assessed by gene-burden analysis (SKAT). SKAT was integrated with differential proteome analysis of toxicity to identify individual proteins coded by genes and/or pathway enrichment putatively controlled by genetic variation associated with anti-CTLA4 related toxicity. Results: The proteomic analysis identified 915 proteins that were differentially expressed (p < 0.05) in non/mild versus sever toxicity outcomes in anti-CTLA4 IT. SKAT analysis of genetic variation identified 1947 significant genes (p < 0.05) associated with toxicity, of which 78 were also significant (p < 0.05) in the proteomic analysis. The functional pathway analysis of 78 proteins showed enrichment for the regulation of interferon production, and a significant enrichment was observed for molecular pathways involved in autoimmunity. Conclusions: We present a novel framework integrating germline genetic information and serum protein expression levels to identify associations with toxicity in anti-CTLA4 IT. We found enrichment for interferon production and pathways involved in autoimmunity controlled by genetic variation. The data strongly support the importance of genetic variation in immune system regulation and its effect on IT-related toxicity. The effect of genetic variants on protein expression is currently further tested in the context of toxicity response to IT treatment. Legal entity responsible for the study: Tomas Kirchoff. and bottom 15 th percentile of expression values. Co-expression of checkpoint markers (TIGIT, FOXP3, LAG3, OX40, TIM3 and IDO) was analyzed within PD-L1-defined categories, along with putative markers of ICI resistance (e.g, VEGF-A/B/C). Tumor mutational burden (TMB; defined as exonic nonsynonymous mutations) was characterized across checkpoints. Results: High PD-L1 expression was strongly associated with high expression of TIGIT, FOXP3 and LAG3 (P < 0.001 for each). In contrast, there was no significant difference in expression of OX40, TIM3 and IDO in groups subdivided by high and low PD-L1 expression. High expression of PD-L1 was associated with elevated levels of VEGF-C, but there was no relationship with VEGF-A or VEGF-B expression. Very limited concordance was seen between elevated TMB (> 200 nonsynonymous mutations) and checkpoint expression. Conclusions: Recent results of combination trials assessing IDO and PD-1 inhibitors may be attributable to a lack of concomitant expression of these markers, thereby limiting synergy. Combinations of PD-1/-L1-directed therapies with TIGIT and LAG3 inhibitors may therefore be of greater interest. Enrichment strategies using TMB for these combinations may be challenging, given the lack of association with checkpoint expression. Legal entity responsible for the study: Sumanta Pal. Background: PF-04518600 (PF-8600) and utomilumab (uto) are human IgG2 agonistic mAbs against the tumor necrosis factor superfamily receptors OX40 and 4-1BB, respectively. Both receptors play key roles in T cell survival, proliferation, and activation. PF-8600 has been shown to increase proliferation and activation of peripheral CD4 memory T cells and uto has a similar effect on CD8 memory T cells. Previously, in patients treated with PF-8600, PD changes have been observed in tumor biopsy samples, including enrichment of gene sets associated with immune activation as well as CD4/8 T cell clonal expansion in peripheral blood. PD changes in tumors and peripheral TCR repertoire for PF-8600 þ uto are reported here. Methods: Paired biopsy samples at baseline and week 6 were collected from 5 dose cohorts (0.1/20, 0.3/20, 0.3/100, 1.0/100, 3.0/100; dose of PF-8600 in mg/kg / flat dose of uto in mg) during dose escalation. Biopsy tissues were analyzed by IHC and RNAseq to evaluate the PD effects of PF-8600 þ uto. CD4, CD8, OX40, and FoxP3 expression was measured by IHC. Changes in transcriptional profile were measured by RNAseq analysis and gene ranking-based gene set enrichment analysis. CD4/8 cells were isolated from blood samples at the same time points. DNA was extracted and submitted for high-throughput sequencing of TCRb.
Results: In an analysis of paired biopsy samples from dose cohorts including 0.3 mg/ kg PF-8600, OX40 was among the genes that showed increased expression. The top gene sets exhibiting significant enrichment by RNAseq were associated with immune activation. TCR sequencing revealed clonal expansion of CD4/8 T cells at all dose levels.
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer with a five-year survival rate that has remained below 10% for the past two decades. While immunotherapy-based treatment in recent years has demonstrated great success in stimulating anti-tumor T cell immunity in a wide variety of cancers, immunotherapy has had very limited success in pancreatic cancer patients. PDAC is characterized by a highly immunosuppressive tumor microenvironment (TME), dominated by Myeloid Derived Suppressor Cells (MDSCs), Type 2 Tumor-Associated Macrophages (M2 TAMs), and T regulatory cells (Tregs). While the presence of these cell types in the PDAC TME is well characterized, much still remains to be understood about how they function within the TME and how they co-operate with each other and tumor-resident lymphocytes to regulate antitumor immunity. Methods: MultiOmyx TM , a novel hyperplexed multi "omic" technology, enables visualization and characterization of multiple biomarkers on a single 4 lm tissue section. MultiOmyx protein immunofluorescence (IF) assays utilize a pair of directly conjugated Cyanine dye-labeled (Cy3, Cy5) antibodies per round of staining. Each round of staining is imaged and followed by novel dye inactivation chemistry, enabling repeated rounds of staining and deactivation for up to 60 protein biomarkers. In this study, MultiOmyx hyperplexed IF assay was utilized to measure CD11b, CD14, CD15, CD16, CD33, CD45RO, CD68, CD163, FoxP3, HLA-DR, Arginase1, PD-1, PD-L1, granzymeB, Ki67, and PanCK protein expression from a single 4 mm FFPE section. Results: Using the MultiOmyx TM multiplexing assay in combination with proprietary algorithms for specific biomarker classification, we will report on the correlation between the presence of monocytic MDSCs (CD11bþCD33þCD14þCD15-HLA-DR-), granulocytic MDSCs (CD11bþCD33þCD15þCD14-HLA-DR-), M2-TAMs (CD68þCD163þ), Tregs (CD3þCD4þFoxP3þ) and the activation state of TILs, as well as their spatial relationship in tumor tissue from patients with PDAC. Conclusions: Using the MultiOmyx TM multiplexing assay will allow us to analyze correlations between immunosuppressive cells and TILs in the pancreatic TME. Legal entity responsible for the study: NeoGenomics. 
